
Dr. Paolo Tarantino discusses treatment selection for patients with hormone receptor-positive, HER2-negative advanced breast cancer harboring an activating AKT1 mutation.

Dr. Paolo Tarantino discusses treatment selection for patients with hormone receptor-positive, HER2-negative advanced breast cancer harboring an activating AKT1 mutation.

Dr. Paolo Tarantino presents a hypothetical case of a 62-year-old postmenopausal woman with hormone receptor-positive, HER2-negative advanced breast cancer.

Matthew A. Gubens, MD, MS, Julia K. Rotow, MD, and Estelamari Rodriguez, MD, MPH, discuss how intracranial activity shapes treatment in ROS1-positive non-small cell lung cancer (NSCLC), a disease with tropism for the brain.

Ana I. Velázquez Mañana, MD, MSc, describes how she discusses durability of benefit with patients who have ROS1-positive non-small cell lung cancer (NSCLC) while many trials remain ongoing.

Explore how tissue biopsies and ctDNA blood tests reveal tumor genetics in metastatic breast cancer, with liquid biopsy offering easier, broader insights.

Learn how to anticipate, monitor, and manage PI3K/AKT therapy side effects in advanced HR-positive, HER2-negative breast cancer after CDK4/6 failure.

Matthew A. Gubens, MD, MS, Julia K. Rotow, MD, and Estelamari Rodriguez, MD, MPH, discuss how to interpret the single-arm trials supporting ROS1 tyrosine kinase inhibitors in ROS1-positive non-small cell lung cancer (NSCLC).

Estelamari Rodriguez, MD, MPH, Julia K. Rotow, MD, and Ana I. Velázquez Mañana, MD, MSc, explain how they choose among guideline-preferred ROS1 tyrosine kinase inhibitors (TKIs) for first-line treatment of non-small cell lung cancer (NSCLC), in a discussion moderated by Matthew A. Gubens, MD, MS.

Estelamari Rodriguez, MD, MPH, explains why patients with advanced non-small cell lung cancer (NSCLC) and high programmed death ligand 1 (PD-L1) expression should not start immunotherapy while biomarker results are pending, since ROS1-positive disease responds poorly to it.

Julia K. Rotow, MD, explains how RNA-based next-generation sequencing (NGS) fits into testing for newly diagnosed advanced nonsquamous non-small cell lung cancer (NSCLC) in a discussion moderated by Matthew A. Gubens, MD, MS, with panelists Estelamari Rodriguez, MD, MPH, and Ana I. Velázquez Mañana, MD, MSc.

Sherry Shen, MD, explains why invasive lobular breast cancer needs histology-specific clinical trials and how its unique biology shapes care.

Real-world ARAAT results show darolutamide plus ADT/docetaxel may offer steroid-free triplet benefits over abiraterone triplet in mHSPC.

Alicia Morgans, MD, MPH, discusses quality-of-life analyses from the ARANOTE and ARASENS trials in metastatic hormone-sensitive prostate cancer.

Martin Dietrich, MD, PhD, names testing as the first gap that remains, followed by a limited understanding of how resistance develops and when to retest.

In this closing segment, Dr. Peter Voorhees, Dr. Luciano Costa, and Dr. Doris Hansen discuss the limitations of available evidence for sequencing therapies in relapsed/refractory multiple myeloma.

In this segment, Dr. Peter Voorhees presents a modified case involving a patient in their early 70s with relapsed multiple myeloma whose disease has become refractory to both lenalidomide and daratumumab following frontline daratumumab, lenalidomide, and dexamethasone therapy.

In this segment, Dr. Peter Voorhees opens the panel discussion on sequencing and patient selection across the multiple myeloma treatment continuum.

In this segment, Dr. Peter Voorhees and Dr. Doris Hansen discuss the safety profile and post-treatment management of CAR T-cell therapy in relapsed/refractory multiple myeloma, with emphasis on considerations for community oncologists caring for patients after discharge from the CAR T-cell center.

In this segment, Dr. Peter Voorhees and Dr. Doris Hansen discuss how the findings from CARTITUDE-2 Cohort A relate to the randomized CARTITUDE-4 study and how these data inform consideration of CAR T-cell therapy in relapsed/refractory multiple myeloma.

In this segment, Dr. Peter Voorhees introduces the role of BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma and its movement into earlier lines of treatment.

In this segment, Dr. Peter Voorhees discusses treatment selection with bispecific antibodies in relapsed/refractory multiple myeloma, focusing on patients with prior CD38 antibody exposure.

In this segment, Dr. Peter Voorhees discusses the MonumenTAL-3 study evaluating the GPRC5D-directed bispecific antibody talquetamab in earlier-line relapsed/refractory multiple myeloma.

In this segment, Dr. Peter Voorhees introduces the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, highlighting the movement of these therapies into earlier lines of treatment.

In this segment, Dr. Luciano Costa provides practical considerations for managing patients with newly diagnosed multiple myeloma receiving frontline quadruplet therapy.

In this segment, Dr. Peter Voorhees and Dr. Luciano Costa discuss how treatment selection can be individualized for patients with newly diagnosed multiple myeloma, including considerations when choosing between triplet and quadruplet regimens.

In this segment, Dr. Peter Voorhees and Dr. Luciano Costa discuss the design and clinical implications of the CEPHEUS trial in newly diagnosed multiple myeloma, with particular attention to patients who were transplant-ineligible or transplant-deferred.

In this segment, Dr. Peter Voorhees introduces the Targeted™ Oncology Investigator Perspectives program and outlines the evolving treatment landscape in newly diagnosed multiple myeloma, including the movement of novel therapies into earlier lines of treatment.

Martin Dietrich, MD, PhD, tells community oncologists to build in access to second opinions, often by telemedicine, and says he would rather be slow and right than fast and wrong, because a less effective first choice drives resistance that later agents cannot fully recover.

Ticiana Leal, MD, argues that trials need more patient-reported outcomes and quality of life measures, since patients with ROS1-positive advanced non-small cell lung cancer now stay on oral therapy for years and the effect on daily life is poorly captured.

Martin Dietrich, MD, PhD, says he manages neurologic adverse events reactively rather than proactively, because he cannot predict who will develop them and because on-target effects tend to appear early.